ASMB - NASDAQ
Assembly Biosciences, Inc.
$24.57
+0.33%Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
At a Glance
Live SnapshotAssembly Biosciences, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Significant working capital drain. Growth may be consuming cash through inventory buildup or receivables extension—monitor closely.
Cash Flow Quality Insight
Exceptional cash generation: High-quality earnings converting to growing free cash flow. The company demonstrates strong pricing power, efficient operations, and disciplined capital allocation.
Assembly Biosciences, Inc. Cash Flow Statement
ASMB • NASDAQ
| Assembly Biosciences, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||||||
-6.1M | -40.2M | -61.2M | -93.1M | -129.9M | -62.2M | -97.6M | -90.8M | -42.8M | -44.3M | -28.5M | -23.8M | -19.4M | -24.8M | -34.3M | -15.3M | -4.5M | -8.8M | |
129K | 129K | 450K | 498K | 466K | 691K | 494K | 643K | 219.2K | 80.3K | 65K | 11K | 6.2K | 4.6K | 3.7K | 12.5K | 7.5K | 4.7K | |
0.0 | 0.0 | 0.0 | 0.0 | -2.5M | 0.0 | -774K | 1.1M | -9.1M | -617.7K | -7.8M | -679.4K | -1.7M | -3.2M | 329K | 2.3M | 117K | 692.9K | |
4.7M | 3.1M | 5.1M | 6.6M | 5.2M | 21.9M | 20.6M | 28.5M | 8.6M | 5M | 7.9M | 11.3M | 1.7M | 3.2M | 3M | 2.4M | 123.8K | 460.8K | |
-1.5M | -2.2M | 2.1M | 3.7M | 44.7M | 7M | 2.8M | -229K | 615.1K | 1.1M | 7.9M | 679.4K | 1.7M | 3.2M | 4M | 8.4M | 767.4K | 902.9K | |
(0.0) | (421K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-38.3M | -11.9M | 76.3M | -2.1M | -11.4M | -30.3M | -9.5M | -4.2M | 44.3M | 3.8M | 1.8M | -2.5M | -111.5K | 234.9K | 2M | -3.1M | 39.9K | 2.6M | |
-41.1M | -51.1M | 22.7M | -84.5M | -93.4M | -63M | -84.1M | -65M | 1.9M | -34.9M | -18.7M | -15M | -17.8M | -21.4M | -25.1M | -5.2M | -3.5M | -4.1M | |
INVESTING ACTIVITIES | ||||||||||||||||||
-66K | -28K | -255K | -102K | -3.1M | -470K | -1.6M | -340K | -864.6K | -146.3K | -58.3K | -150K | -6.5K | -3.2K | -12K | (0.0) | -2.6K | -2.9K | |
(0.0) | (0.0) | (0.0) | (1.5M) | (1.5M) | (0.0) | -1.7M | -48.9M | -33.2B | -36.2B | (150.0) | (509.4K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-232.2M | -90.5M | -133.9M | -27.6M | -160.4M | -193.2M | -281.3M | -183.9M | -48.2M | -8M | -69.8M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
116.4M | 130.7M | 65M | 116.8M | 187.7M | 263.5M | 232.6M | 48.9M | 33.5M | 44.3M | 5M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
2.3M | 0.0 | 24K | 0.0 | 857K | -1.8M | 1.7M | 48.9M | 33.2B | 36.2B | 150.0 | -82K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-113.5M | (40.2M) | -69.1M | (90.6M) | (26.5M) | (68.1M) | -50.3M | -135.4M | -15.6M | (36.2M) | -64.9M | (277.4K) | -6.5K | -3.2K | -12K | (0.0) | -2.6K | -2.9K | |
FINANCING ACTIVITIES | ||||||||||||||||||
174.7M | 29.3M | 13.7M | 325K | 52.8M | 5.5M | 134.7M | 155.4M | 64.8M | 152.6K | 81M | 16.7M | 24.4M | 4.2M | 50M | 15.2M | 0.0 | 1.1M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -2.8M | 5.3M | 3.6M | 1.7M | |
0.0 | 155K | 129K | 289K | 258K | 2.1M | 5M | 4.4M | 0.0 | 0.0 | 554.3K | 0.0 | 0.0 | 730.3K | 288.7K | -755.1K | -76.5K | -312.9K | |
174.7M | 29.4M | 13.8M | 614K | 53.1M | 7.6M | 139.6M | 159.8M | 67.2M | 152.6K | 81.6M | 16.7M | 24.4M | 4.9M | 47.5M | 19.7M | 3.6M | 2.5M | |
CASH FLOW SUMMARY | ||||||||||||||||||
20.1M | 18.5M | -32.6M | 6.8M | -13.8M | 12.7M | 5.3M | -40.6M | 53.5M | 1.5M | -2M | 2M | 6.6M | -16.5M | 22.4M | 14.5M | 65.4K | -1.7M | |
38.3M | 19.8M | 52.4M | 45.6M | 59.4M | 46.7M | 41.5M | 82M | 28.6M | 27.1M | 29.1M | 27.1M | 20.5M | 37M | 14.6M | 81.3K | 15.9K | 1.7M | |
58.5M | 38.3M | 19.8M | 52.4M | 45.6M | 59.4M | 46.7M | 41.5M | 82M | 28.6M | 27.1M | 29.1M | 27.1M | 20.5M | 37M | 14.6M | 81.3K | 15.9K | |
-41.2M | -51.1M | 22.5M | -84.6M | -96.5M | -65.2M | -85.6M | -65.3M | 995.5K | -35M | -18.8M | -15.1M | -17.8M | -21.4M | -25.1M | -5.2M | -3.5M | -4.2M |
SEC Filings
ASMB - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 26, 2026 | May 21, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 22, 2026 | May 22, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 22, 2026 | June 04, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 30, 2026 | March 24, 2026 | 2026 | |
S-3 S-3 N/A | March 19, 2026 | March 19, 2026 | ||
10-K 10-K 2025 FY FY | March 19, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 19, 2026 | March 19, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 08, 2025 | December 08, 2025 | 2025 |
Related Guides
Continue your ASMB research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.